Skip to main content

Japanese Pharma Fujisawa Invests in Quark Biotech

NEW YORK, June 27 - Japanese pharmaceutical company Fujisawa has made an undisclosed equity investment in Quark Biotech (QBI), the companies said Wednesday. 

The investment is meant to accelerate the two companies' current collaboration, which dates to April 1999, Fujisawa said in a statement. At that time, Fujisawa agreed to pay research fees and milestone payments valued at $19 million for QBI, a genomics-based biopharmaceutical company based in Chicago, to discover genes related to stroke and develop drugs that target those genes. 

"The financial investment by Fujisawa is a tremendous affirmation of our mission to apply QBI's powerful genomic technology platform to the creation of promising new medicines for difficult-to-treat diseases, such as stroke," said Daniel Zurr, chief executive officer and founder of QBI, in a statement.

QBI also has research collaborations with other pharmaceutical companies, including Sankyo and Taisho Pharmaceutical, both based in Tokyo, to apply its gene expression and protein profiling technologies toward identifying drug targets and developing pharmaceuticals. QBI's research facilities are located in Israel and Chicago.  
The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.